184 related articles for article (PubMed ID: 25677408)
21. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors.
Mease PJ
Ann Rheum Dis; 2002 Apr; 61(4):298-304. PubMed ID: 11874829
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
Kristensen LE; Gülfe A; Saxne T; Geborek P
Ann Rheum Dis; 2008 Mar; 67(3):364-9. PubMed ID: 17644547
[TBL] [Abstract][Full Text] [Related]
23. Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort.
Eder L; Chandran V; Schentag CT; Shen H; Cook RJ; Gladman DD
Rheumatology (Oxford); 2010 Jul; 49(7):1361-6. PubMed ID: 20385615
[TBL] [Abstract][Full Text] [Related]
24. Sex Differences in the Treatment of Psoriatic Arthritis: A Systematic Literature Review.
Generali E; Sciré CA; Cantarini L; Selmi C
Isr Med Assoc J; 2016; 18(3-4):203-8. PubMed ID: 27228644
[TBL] [Abstract][Full Text] [Related]
25. Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping.
Stekhoven D; Scherer A; Nissen MJ; Grobéty V; Yawalkar N; Villiger PM; Möller B;
Clin Rheumatol; 2017 Sep; 36(9):2035-2043. PubMed ID: 28432523
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis and management of psoriatic arthritis.
Balakrishnan C; Madnani N
Indian J Dermatol Venereol Leprol; 2013 Jul; 79 Suppl 7():S18-24. PubMed ID: 23974691
[TBL] [Abstract][Full Text] [Related]
27. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis.
Ravindran V; Scott DL; Choy EH
Ann Rheum Dis; 2008 Jun; 67(6):855-9. PubMed ID: 17827183
[TBL] [Abstract][Full Text] [Related]
28. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
Toussirot É; Houvenagel É; Goëb V; Fouache D; Martin A; Le Dantec P; Dernis E; Wendling D; Ansemant T; Berthelot JM; Bader-Meunier B; Kantelip B;
Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
[TBL] [Abstract][Full Text] [Related]
29. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era.
Gladman DD; Ziouzina O; Thavaneswaran A; Chandran V
J Rheumatol; 2013 Aug; 40(8):1357-9. PubMed ID: 23818708
[TBL] [Abstract][Full Text] [Related]
30. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.
Caso F; Cantarini L; Morisco F; Del Puente A; Ramonda R; Fiocco U; Lubrano E; Peluso R; Caso P; Galeazzi M; Punzi L; Scarpa R; Costa L
Expert Opin Biol Ther; 2015 May; 15(5):641-50. PubMed ID: 25652590
[TBL] [Abstract][Full Text] [Related]
31. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
Brocq O; Roux CH; Albert C; Breuil V; Aknouche N; Ruitord S; Mousnier A; Euller-Ziegler L
Joint Bone Spine; 2007 Mar; 74(2):148-54. PubMed ID: 17368068
[TBL] [Abstract][Full Text] [Related]
32. Four cases of Japanese patients with psoriatic arthritis in whom effective treatments by anti-tumor necrosis factor-α drugs were evaluated by magnetic resonance imaging together with improvement of skin lesions.
Yonenaga T; Saeki H; Nakagawa H; Fukuchi O; Umezawa Y; Hayashi M; Ito T; Yanaba K; Tojyo S; Fukuda K
J Dermatol; 2015 Jan; 42(1):49-55. PubMed ID: 25425546
[TBL] [Abstract][Full Text] [Related]
33. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.
Lahiri M; Teng GG; Cheung PP; Suresh E; Chia FL; Lui NL; Koh DR; Koh WH; Leong KP; Lim AYN; Ng SC; Thumboo J; Lau TC; Leong KH
Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916
[TBL] [Abstract][Full Text] [Related]
34. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
[TBL] [Abstract][Full Text] [Related]
35. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
[TBL] [Abstract][Full Text] [Related]
36. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.
Michelsen B; Kristianslund EK; Hammer HB; Fagerli KM; Lie E; Wierød A; Kalstad S; Rødevand E; Krøll F; Haugeberg G; Kvien TK
Ann Rheum Dis; 2017 Apr; 76(4):708-711. PubMed ID: 27707730
[TBL] [Abstract][Full Text] [Related]
37. Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature.
Reddy SM; Crean S; Martin AL; Burns MD; Palmer JB
Clin Rheumatol; 2016 Dec; 35(12):2955-2966. PubMed ID: 27730309
[TBL] [Abstract][Full Text] [Related]
38. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
[TBL] [Abstract][Full Text] [Related]
39. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
[TBL] [Abstract][Full Text] [Related]
40. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors.
Finzel S; Kraus S; Schmidt S; Hueber A; Rech J; Engelke K; Englbrecht M; Schett G
Ann Rheum Dis; 2013 Jul; 72(7):1176-81. PubMed ID: 22915620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
